FDA 483 - Lonza AG - March 29, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Lona Pharma and Biotech in Visp, Switzerland, a drug substance manufacturer, was cited with five observations during an FDA inspection from March 25-29, 2019. The observations primarily concern inadequate testing and storage of intermediates and drug substances, deficiencies in validation studies, and issues with raw material handling, pest control, and QC analytical procedures. These findings indicate significant concerns regarding quality control and manufacturing practices.
ID · d2b94531-82a9-47ee-8dfc-06a69d21c1c6